Acquired by Oracle
Industries BiotechnologyClinical TrialsComputerData Collection and LabelingData ManagementElectronicsEnterprise SoftwareInformation TechnologyMedicalSoftwareHeadquarters Regions Greater Boston Area, East Coast, New England Closed Date Apr 2010 Founded Date 1997 Founders Gus Lawlor, Paul Bleicher, Richard Dale Operating Status Closed Last Funding Type Venture - Series Unknown
Stock Symbol NASDAQ:PFWD Company Type For Profit
Contact Email info@phaseforward.com Phone Number 17818907878
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward's technology and global services are designed to enable life sciences companies to automate and integrate the management of their entire clinical development process, from study initiation and FDA submission through
post-marketing studies.
Until its acquisition by Oracle in April 2010, Phase Forward was a publicly held company. Its corporate headquarters were in Waltham, Massachusetts, international headquarters in Maidenhead, UK, and its regional offices in the U.S., Japan, France and Australia.
Phase Forward was founded in 1997 by Paul Bleicher, M.D, Ph.D., who had experienced firsthand the complexities involved in developing and conducting paper-based trials, in particular, capturing, managing, and growing volumes of data. Dr. Bleicher's vision was to develop technology that would enable organizations to make the shift from paper-based methods to Internet-enabled solutions. His pioneering efforts have contributed significantly to Phase Forward's evolution from initial concept to its current industry-leading position.
Spearheading the evolution of electronic data capture (EDC) with its industry-leading InForm solution, Phase Forward transformed the way clinical data are collected, analyzed and managed. With the acquisition of Lincoln Technologies' innovative safety management solutions, Phase Forward took steps to provide the end-to-end solutions customers need to track and monitor product efficacy and safety, while building their trials more efficiently and cost-effectively.
Transaction Name Phase Forward acquired by OracleAcquired by OracleAnnounced Date Apr 20, 2010 Price $685M